“Monoclonals safest weapon for fragile patients”

On the sidelines of the meeting “mAbs in the Early Treatment. Controversies and consensus in the frail patient with Covid-19: we do not create antibodies”, promoted in Rome by GlaxoSmithKline and dedicated to the discussion of the best treatment options for frail patients who contract Covid-19, Massimo Andreoni, scientific director of the Italian Society of infectious and tropical diseases (Simit).